Abstract
To the Editor: We report the preliminary results of a prospective clinical study in which two patients with psoriasis, psoriatic arthritis (PsA), and chronic hepatitis C virus (HCV) infection received etanercept. Its effect on liver disease was monitored by the periodic measurement of serum transaminase and viral load. Liver biopsy specimens were obtained at baseline and 12 months into treatment. The literature was reviewed for papers describing tumor necrosis factor–alfa (TNFα) antagonist administration to patients with chronic HCV and autoimmune diseases (Table I; available online at http://www.eblue.org).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
